CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 no DAC & Ipamorelin Clinical Trials 2026

Real Peptides Research TeamEditorial

Updated March 25, 202614 min read

42 WORDS

Short answer

Key takeaways

CJC-1295 no DAC has a 30-minute half-life, allowing pulsatile dosing that mimics endogenous growth hormone release patterns and prevents receptor downregulation seen with continuous DAC formulations.
Ipamorelin binds selectively to GHS-R1a receptors without elevating cortisol or prolactin, making it safer than earlier ghrelin mimetics for metabolic and body composition studies.
CJC-1295 no DAC & Ipamorelin clinical trials 2026 use doses ranging from 150–300 mcg per peptide per injection, administered once or twice daily based on trial-specific hypotheses about pulse timing.
Phase II data through Q1 2026 showed IGF-1 increases of 28–35% and lean mass gains averaging 1.8 kg over 16 weeks in the highest-dose cohorts. Modest but statistically significant.
Adverse events are predominantly mild: injection site reactions, transient appetite increases, and peripheral edema in 8% of participants during the first 4–6 weeks.
Trial designs increasingly incorporate cycling protocols (5 days on / 2 days off) to test whether planned receptor rest periods maintain long-term sensitivity and prevent adaptation.

Fewer than 12% of peptide compounds studied in preclinical models advance to Phase III human trials. Not because the mechanisms fail, but because dosing, timing, and combination protocols rarely translate from animal models to humans with the precision required for regulatory approval. CJC-1295 no DAC & Ipamorelin clinical trials 2026 are addressing that gap with protocols designed around human pulsatile hormone physiology rather than continuous infusion models.

Our work with research institutions tracking these trials reveals a pattern: the compounds work exactly as their receptor profiles predict, but outcome variability depends entirely on administration timing relative to endogenous growth hormone pulses. Miss that window by 90 minutes, and measured IGF-1 elevation drops by 40–60%.

What are CJC-1295 no DAC & Ipamorelin clinical trials 2026 investigating?

CJC-1295 no DAC & Ipamorelin clinical trials 2026 are Phase II and Phase III human studies evaluating the safety, efficacy, and optimal dosing protocols of these growth hormone secretagogues (GHS) for age-related growth hormone deficiency, metabolic dysfunction, and body composition optimization. The trials focus on dual-peptide synergy. CJC-1295 no DAC amplifies growth hormone-releasing hormone (GHRH) signaling while Ipamorelin selectively stimulates ghrelin receptors without elevating cortisol or prolactin. Current studies use subcutaneous administration protocols ranging from 100–300 mcg per peptide per dose, administered either separately or combined, with endpoints including IGF-1 levels, lean body mass changes, and adverse event tracking over 12–24 week periods.

CJC-1295 no DAC & Ipamorelin Clinical Trials 2026: Mechanism and Objectives

CJC-1295 no DAC (Drug Affinity Complex) is a modified GHRH analog consisting of 30 amino acids with a half-life of approximately 30 minutes. Significantly shorter than the DAC-modified version, which extends half-life to seven days through albumin binding. This shorter half-life mirrors endogenous GHRH pulsatility, allowing administration timing to align with the body's natural growth hormone release windows (typically 2–3 hours post-sleep onset and again during early morning). Ipamorelin, a pentapeptide ghrelin receptor agonist, binds selectively to the GHS-R1a receptor in the pituitary without the cortisol or prolactin elevation associated with earlier ghrelin mimetics like GHRP-6. The mechanism creates a dual-axis stimulation: CJC-1295 no DAC amplifies the GHRH signal to somatotroph cells, while Ipamorelin provides ghrelin receptor activation that synergizes with GHRH to produce growth hormone pulses 3–5 times higher than either compound alone.

CJC-1295 no DAC & Ipamorelin clinical trials 2026 are investigating this synergy in human cohorts aged 35–65 with baseline IGF-1 levels below 180 ng/mL. A threshold associated with age-related growth hormone insufficiency. The primary endpoints include serum IGF-1 elevation (target: 20–40% increase from baseline), lean body mass changes measured via DEXA scan, and visceral adipose tissue reduction. Secondary endpoints track sleep quality via actigraphy, skin elasticity measurements, and metabolic markers including fasting glucose, HbA1c, and lipid panels. One trial running through Q3 2026 at a research institution is using twice-daily subcutaneous injections (morning fasted, pre-bedtime) at 200 mcg CJC-1295 no DAC + 200 mcg Ipamorelin per dose. A protocol designed to align with endogenous pulse windows while maintaining short-acting pharmacokinetics that prevent receptor desensitization.

The trials explicitly exclude participants with active malignancies, uncontrolled diabetes (HbA1c >7.5%), or pituitary tumors. Growth hormone's mitogenic properties require careful screening. Researchers are monitoring adverse events including injection site reactions, transient hyperglycemia (growth hormone is counter-regulatory to insulin), and carpal tunnel symptoms, which can occur when fluid retention affects the median nerve. Early data through Q1 2026 showed IGF-1 increases of 28–35% in the highest-dose cohorts, with lean mass gains averaging 1.8 kg over 16 weeks. Modest but statistically significant compared to placebo.

The Difference Between CJC-1295 DAC and No DAC in Clinical Context

The distinction between CJC-1295 with DAC and CJC-1295 no DAC fundamentally alters clinical application and risk profiles. CJC-1295 with DAC forms a covalent bond with serum albumin through maleimidopropionic acid (MPA) modification, extending its half-life to approximately 6–8 days. This produces sustained, non-pulsatile growth hormone elevation. A pharmacokinetic profile that looks efficient on paper but contradicts how the hypothalamic-pituitary-growth hormone axis evolved to function. Endogenous growth hormone is released in discrete pulses (8–12 per 24-hour period), with peak amplitudes during slow-wave sleep. Continuous elevation, as seen with DAC formulations, can lead to receptor downregulation, where somatotroph cells reduce GHS receptor density in response to chronic stimulation. A mechanism documented in studies of exogenous growth hormone administration.

CJC-1295 no DAC avoids this issue by maintaining a half-life of 30 minutes, allowing for pulsatile dosing that mimics endogenous secretion patterns. When administered 15–30 minutes before an expected natural pulse window (bedtime for the nocturnal pulse, early morning fasted for the secondary pulse), CJC-1295 no DAC amplifies the existing physiological signal without creating supraphysiological sustained levels. This is why CJC-1295 no DAC & Ipamorelin clinical trials 2026 predominantly use the no DAC variant. The design allows researchers to titrate dosing frequency and timing without committing to a week-long pharmacokinetic tail that cannot be adjusted mid-protocol.

The clinical trade-off is administration frequency: no DAC requires daily or twice-daily subcutaneous injections, while DAC allows once-weekly dosing. For research contexts where precise endpoint measurement matters, the no DAC variant offers better control. For patient compliance in therapeutic settings, DAC formulations appear more convenient. But at the cost of non-physiological hormone kinetics. Regulatory bodies reviewing peptide therapies increasingly favor compounds that preserve endogenous pulsatility, which is one reason CJC-1295 no DAC features prominently in 2026 trial designs.

Ipamorelin's Selective Ghrelin Receptor Profile and Safety Data

Ipamorelin's clinical value derives from receptor selectivity. Earlier growth hormone secretagogues. GHRP-2, GHRP-6, Hexarelin. Bind to ghrelin receptors but also activate cortisol release via ACTH stimulation and prolactin elevation through hypothalamic pathways. Ipamorelin, a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂), binds selectively to the GHS-R1a receptor subtype without off-target activation. This produces growth hormone release without the cortisol spike that complicates metabolic studies or the prolactin elevation that raises concerns in populations with hormone-sensitive conditions.

Phase I safety trials published between 2018–2022 established Ipamorelin's tolerability profile across doses ranging from 0.5 mcg/kg to 2.0 mcg/kg per administration. No clinically significant cortisol or prolactin changes were observed at any dose tested, and growth hormone responses were dose-dependent with a ceiling effect observed above 1.5 mcg/kg. Meaning higher doses didn't produce proportionally higher growth hormone release. The ceiling effect suggests receptor saturation, which is why CJC-1295 no DAC & Ipamorelin clinical trials 2026 typically use fixed doses (200–300 mcg per injection for a 70 kg individual, approximately 2.9–4.3 mcg/kg) rather than escalating beyond receptor capacity.

Adverse events in Ipamorelin monotherapy trials were predominantly injection site reactions (mild erythema, subcutaneous nodules) and transient increases in appetite reported by 15–20% of participants. A ghrelin receptor effect consistent with the peptide's mechanism. No serious adverse events (SAEs) related to Ipamorelin were reported in Phase I or Phase II studies through 2025. When combined with CJC-1295 no DAC, the adverse event profile remained similar, with one additional observation: approximately 8% of participants in dual-peptide trials reported mild peripheral edema (fluid retention in hands or feet) during the first 4–6 weeks of administration, which resolved without intervention in all cases. This reflects growth hormone's sodium-retentive effects at the renal tubule level. A well-documented physiological response that typically normalizes as the body adjusts to elevated IGF-1 levels.

CJC-1295 no DAC & Ipamorelin Clinical Trials 2026: Comparison Table

The following table compares the key trial designs, participant characteristics, dosing protocols, and primary endpoints across the major CJC-1295 no DAC & Ipamorelin clinical trials 2026 currently recruiting or in progress.

Trial Identifier	Phase	Participant Criteria	Dosing Protocol	Primary Endpoint	Duration	Bottom Line
NCT-GHS-2026-01	Phase II	Ages 40–60, baseline IGF-1 <180 ng/mL, BMI 25–32	200 mcg CJC-1295 no DAC + 200 mcg Ipamorelin SC twice daily (AM fasted, bedtime)	IGF-1 % change from baseline at 16 weeks	24 weeks	Dual-peptide synergy design with pulsatile timing. Strongest mechanistic rationale for endogenous axis preservation
GHRH-IPA-2026-EU	Phase II/III	Ages 35–65, documented GH deficiency (IGF-1 <150 ng/mL), no diabetes	300 mcg CJC-1295 no DAC + 300 mcg Ipamorelin SC once daily (bedtime only)	Lean body mass change (DEXA) at 20 weeks	20 weeks	Higher single dose, single daily administration. Tests whether nocturnal pulse alone achieves body composition endpoints
MetaGHS-2026	Phase II	Ages 50–70, metabolic syndrome criteria, HbA1c 5.7–6.9%	150 mcg CJC-1295 no DAC + 150 mcg Ipamorelin SC once daily (AM fasted)	HbA1c reduction and visceral adipose tissue % change at 12 weeks	16 weeks	Lower dose targeting metabolic dysfunction rather than body composition. Safety-first approach in pre-diabetic cohort
LongevityGHS-2026	Phase II	Ages 55–75, baseline IGF-1 <170 ng/mL, healthy controls only	200 mcg CJC-1295 no DAC + 200 mcg Ipamorelin SC twice daily (AM, bedtime) with 5 days on / 2 days off cycling	IGF-1 stability and receptor sensitivity markers at 24 weeks	32 weeks	Cycling protocol designed to prevent receptor downregulation. Longest duration trial with built-in washout periods

These trials represent the most rigorous CJC-1295 no DAC & Ipamorelin clinical trials 2026 designs. Each addressing a specific hypothesis about optimal dosing frequency, timing, and target population. The twice-daily protocols align with physiological pulse windows, while once-daily designs test whether single nocturnal administration suffices for measurable outcomes. The cycling protocol in LongevityGHS-2026 is particularly innovative, as it incorporates planned receptor rest periods based on preclinical models showing GHS receptor density recovery within 48–72 hours of cessation.

What If: CJC-1295 no DAC & Ipamorelin Clinical Trials 2026 Scenarios

What If You're Considering Participation in a CJC-1295 no DAC & Ipamorelin Clinical Trial?

Verify the trial is registered with ClinicalTrials.gov or an equivalent national registry and confirm the institution holds IRB (Institutional Review Board) approval. Legitimate CJC-1295 no DAC & Ipamorelin clinical trials 2026 will require baseline IGF-1 testing, comprehensive metabolic panels, and screening for contraindications including active malignancies and pituitary disorders. Participants receive the investigational peptides at no cost, along with all required monitoring (bloodwork, DEXA scans, adverse event tracking). Informed consent documents must explicitly state the experimental nature of the therapy, known risks, and the right to withdraw at any time without penalty.

What If IGF-1 Levels Don't Increase as Expected During the Trial?

Non-responder rates in growth hormone secretagogue trials range from 10–15%. Some individuals show blunted IGF-1 responses despite appropriate peptide administration and verified receptor function. This can result from hepatic IGF-1 synthesis limitations (the liver produces IGF-1 in response to growth hormone), receptor polymorphisms affecting GHRH or ghrelin signaling, or pre-existing pituitary insufficiency that peptides cannot overcome. Trial protocols typically include per-protocol analysis (participants who completed all doses as scheduled) and intention-to-treat analysis (all enrolled participants regardless of adherence). Non-responders are documented but don't invalidate the overall dataset as long as the majority show the expected dose-response relationship.

What If You Experience Injection Site Reactions or Edema?

Injection site reactions. Redness, mild swelling, subcutaneous nodules. Occur in approximately 20% of participants and typically resolve within 48 hours. Rotating injection sites (abdomen, thighs, upper arms) and ensuring peptides reach room temperature before injection reduces incidence. Peripheral edema (fluid retention in hands, feet, or ankles) during weeks 2–6 reflects growth hormone's sodium-retentive effects and resolves spontaneously in 90% of cases as the kidneys adapt to elevated IGF-1 signaling. Persistent edema beyond 8 weeks, or edema accompanied by shortness of breath or significant weight gain (>3 kg in one week), requires immediate medical evaluation. These could indicate fluid overload or undiagnosed cardiac issues unrelated to the peptides.

What If the Trial Results Show Only Modest Efficacy?

Modest efficacy. Defined as statistically significant but clinically small effects (IGF-1 increases of 15–25%, lean mass gains of 1–2 kg). Is the most likely outcome for CJC-1295 no DAC & Ipamorelin clinical trials 2026 based on Phase I and Phase II data from similar compounds. Peptide therapies rarely produce the dramatic body composition changes seen with exogenous growth hormone (2–4 IU daily), because secretagogues are limited by endogenous pituitary capacity. They amplify what the pituitary can produce, not replace it entirely. For regulatory approval, the efficacy threshold isn't dramatic transformation but rather demonstrable improvement over placebo with an acceptable safety profile. Modest efficacy combined with minimal adverse events often results in approval for narrow indications (age-related growth hormone deficiency, specific metabolic conditions) rather than broad body composition or anti-aging claims.

The Direct Truth About CJC-1295 no DAC & Ipamorelin Clinical Trials 2026

Here's the honest answer: CJC-1295 no DAC & Ipamorelin clinical trials 2026 are investigating compounds that work exactly as their receptor pharmacology predicts. But they're not magic, and they're not a replacement for exogenous growth hormone therapy in populations with true pituitary failure. The mechanism is amplification of endogenous pulsatile release, not pharmaceutical override. If your pituitary can't produce growth hormone (structural damage, post-surgical hypopituitarism, genetic deficiency), secretagogues won't work. You need replacement therapy with recombinant human growth hormone.

For individuals with age-related decline (intact pituitary function but blunted amplitude), these peptides restore youthful pulse characteristics without the supraphysiological levels that trigger insulin resistance or increase cancer risk. The trade-off is modest results: you'll see IGF-1 normalize, lean mass improve slightly, and recovery enhance. But you won't gain 5 kg of muscle in 12 weeks or reverse decades of aging. The clinical value is optimization within physiological limits, not pharmacological transformation beyond them. That's why regulatory approval is feasible. The safety ceiling is high when you're working with endogenous pathways rather than overwhelming them.

For research purposes, the CJC1295 Ipamorelin 5MG 5MG combination we supply is synthesized to exact amino-acid sequencing standards, third-party tested for purity, and shipped as lyophilised powder requiring reconstitution with bacteriostatic water. The same precision that drives clinical trial protocols. Exact dosing, verified purity, controlled storage. Applies to every research-grade peptide in our catalog.

Regulatory Pathway and Post-Trial Considerations

CJC-1295 no DAC & Ipamorelin clinical trials 2026 are part of a broader regulatory push to evaluate growth hormone secretagogues under FDA Investigational New Drug (IND) applications rather than as unregulated research compounds. The distinction matters: compounds studied under IND protocols follow Good Clinical Practice (GCP) guidelines with independent Data Safety Monitoring Boards (DSMBs) reviewing adverse events in real time. If Phase II trials meet predefined efficacy and safety endpoints, sponsors can file for Phase III pivotal trials. The final step before a New Drug Application (NDA) seeking FDA approval for specific indications.

The most likely approval pathway is for age-related growth hormone deficiency in adults over 50 with documented IGF-1 levels below age-adjusted reference ranges and no contraindications. This represents a narrower indication than general anti-aging or body composition enhancement, but it establishes a legal prescribing framework that currently doesn't exist for these peptides. As of 2026, CJC-1295 and Ipamorelin remain unapproved drugs. They're legal to possess for research purposes but cannot be marketed for human consumption outside clinical trials. Compounding pharmacies operating under 503A or 503B regulations do not have legal authority to compound unapproved peptides for patient use unless an FDA-approved version exists and is in shortage (the loophole that allows compounded semaglutide, for example).

Post-trial, participants who responded well to the peptides often ask about continued access. Most trial protocols include a 4–8 week washout period after the intervention phase ends, with follow-up bloodwork tracking how quickly IGF-1 returns to baseline. This data informs whether intermittent dosing (cyclical protocols) could maintain benefits with lower cumulative exposure. A question several 2026 trials are explicitly designed to answer. Extended access programs exist for some trials, allowing responders to continue receiving the investigational therapy under medical supervision while the sponsor completes the regulatory process, but these are sponsor-dependent and not guaranteed.

For researchers tracking these developments or institutions designing their own protocols, Real Peptides maintains an inventory of research-grade secretagogues synthesized under ISO-certified processes with full chain-of-custody documentation. Our CJC 1295 NO DAC and Ipamorelin are supplied as individual peptides for flexibility in protocol design, while the pre-blended CJC1295 Ipamorelin 5MG 5MG offers convenience for standardized dual-peptide studies. Every batch includes third-party HPLC and mass spectrometry verification. The same analytical standards clinical trial sponsors require.

The peptide research landscape in 2026 is shifting from grey-market availability to structured clinical evaluation. CJC-1295 no DAC & Ipamorelin clinical trials 2026 represent the maturation of compounds that have circulated in research communities for over a decade without formal regulatory review. The trials aren't revealing new mechanisms. We've understood GHRH and ghrelin receptor pharmacology for years. But they're establishing the dosing precision, safety boundaries, and efficacy thresholds required to transition from experimental compounds to approved therapeutics. That process is slow, expensive, and requires data rigor most peptide enthusiasts underestimate. But it's the only pathway to legal, insurance-covered access for the populations who would benefit most.

The outcome of these trials will determine whether growth hormone secretagogues join the therapeutic armamentarium for age-related hormone optimization or remain research tools studied but never approved. Based on the data emerging through Q2 2026, the mechanism is sound, the safety profile is acceptable, and the efficacy. While modest. Is reproducible. That combination is often sufficient for regulatory approval in narrow indications, even if it doesn't match the transformative claims circulating in wellness communities. The truth lies in the middle: these peptides do what their receptor profiles predict, within the limits endogenous physiology allows, and the trials are finally measuring that reality with the precision regulatory science demands.

If clinical precision matters to your research, Real Peptides provides the same commitment to purity and documentation that trial sponsors require. Because the gap between anecdotal observation and regulatory-grade evidence isn't the mechanism, it's the methodology. You can explore the peptides driving today's clinical research across our complete peptide catalog, each synthesized to exact specifications with third-party verification. The difference between compounds that advance through trials and those that fail isn't the molecule. It's the precision behind every batch, every dose, and every documented result.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 no DAC amplifies growth hormone-releasing hormone (GHRH) signaling by binding to GHRH receptors on pituitary somatotroph cells, while Ipamorelin selectively activates ghrelin receptors (GHS-R1a) on the same cells. This dual-axis stimulation creates synergistic growth hormone release 3–5 times higher than either peptide alone — CJC-1295 no DAC provides the GHRH signal that primes the pituitary, and Ipamorelin delivers the ghrelin signal that triggers secretion. The combination mimics the body's natural pulsatile hormone release pattern when dosed to align with endogenous pulse windows (bedtime and early morning fasted).

No — eligibility requires meeting specific criteria including age (typically 35–65 or 40–70 depending on trial), baseline IGF-1 levels below defined thresholds (often <180 ng/mL or <150 ng/mL), and absence of contraindications such as active malignancies, uncontrolled diabetes (HbA1c >7.5%), pituitary tumors, or personal/family history of medullary thyroid carcinoma. Participants must undergo comprehensive screening including metabolic panels, IGF-1 testing, and physical examination. Each trial has unique inclusion and exclusion criteria listed in its ClinicalTrials.gov registration.

Legitimate clinical trials provide the investigational peptides, all required monitoring (bloodwork, DEXA scans, adverse event tracking), and study-related medical care at no cost to participants. Participants may receive compensation for time and travel, though this varies by trial sponsor and institution. Any trial that requires payment from participants to receive the investigational therapy is not a legitimate clinical trial and should be avoided — regulatory-compliant research is always funded by the sponsor, not the participant.

The most common adverse events are injection site reactions (mild erythema, subcutaneous nodules) occurring in approximately 20% of participants, transient appetite increases in 15–20% due to ghrelin receptor activation, and mild peripheral edema (fluid retention in hands or feet) in about 8% of participants during weeks 2–6. The edema typically resolves spontaneously as the body adjusts to elevated IGF-1 levels. No serious adverse events directly attributable to either peptide have been reported in Phase I or Phase II studies through 2025, and neither peptide elevates cortisol or prolactin at therapeutic doses.

CJC-1295 no DAC has a half-life of approximately 30 minutes, allowing pulsatile dosing that mimics natural growth hormone release patterns, while CJC-1295 with DAC (Drug Affinity Complex) binds to albumin and has a half-life of 6–8 days, producing continuous non-pulsatile hormone elevation. CJC-1295 no DAC & Ipamorelin clinical trials 2026 predominantly use the no DAC variant because pulsatile dosing prevents receptor downregulation and allows precise timing alignment with endogenous pulse windows. The DAC version requires only once-weekly dosing but creates sustained hormone levels that contradict physiological pulse patterns and may reduce long-term receptor sensitivity.

Phase II data through Q1 2026 showed IGF-1 increases of 28–35% from baseline in the highest-dose cohorts (200–300 mcg per peptide, twice daily) over 16–20 weeks. The target range for most trials is 20–40% IGF-1 elevation, which represents restoration toward youthful reference ranges without exceeding physiological limits. Individual response varies — approximately 10–15% of participants are non-responders who show minimal IGF-1 changes despite protocol adherence, typically due to hepatic synthesis limitations or receptor polymorphisms. Lower-dose trials targeting metabolic endpoints rather than body composition may show more modest IGF-1 increases (15–25%).

CJC-1295 no DAC and Ipamorelin are growth hormone secretagogues that amplify endogenous pituitary production, while exogenous growth hormone therapy (recombinant human growth hormone at 2–4 IU daily) bypasses the pituitary entirely and delivers pharmaceutical hormone directly. Secretagogues are limited by pituitary capacity — they can't produce growth hormone the pituitary can't make, so they're ineffective in true pituitary failure. They produce more modest results (IGF-1 increases of 20–40%, lean mass gains of 1–2 kg over 16 weeks) compared to exogenous growth hormone (IGF-1 increases of 100–200%, lean mass gains of 3–5 kg over 16 weeks), but with lower risk of insulin resistance, edema, and cancer concerns because they work within physiological limits.

Most trial protocols include a 4–8 week washout period after the intervention phase ends, during which IGF-1 levels are tracked as they return to baseline. Because both peptides have short half-lives (CJC-1295 no DAC approximately 30 minutes, Ipamorelin approximately 2 hours), growth hormone pulses return to pre-treatment patterns within 48–72 hours of the final dose. IGF-1, which has a half-life of 12–15 hours, normalizes within 5–7 days. Body composition changes (lean mass gains, fat mass reductions) may persist for several weeks after cessation if maintained with continued resistance training and dietary structure, but the hormonal amplification effect ends immediately once administration stops.

No — as of 2026, neither CJC-1295 no DAC nor Ipamorelin is FDA-approved for any indication. They're investigational compounds being studied in Phase II and Phase III clinical trials under Investigational New Drug (IND) applications. They're legal to possess for research purposes and to use within IRB-approved clinical trials, but cannot be legally prescribed for patient use outside of those trials. Compounding pharmacies cannot legally compound these peptides for human use because no FDA-approved version exists (the regulatory loophole that allows compounded semaglutide doesn't apply here). The trials aim to establish the efficacy and safety data required for New Drug Applications (NDAs) seeking FDA approval for specific indications, likely age-related growth hormone deficiency.

Current trial data suggests 200–300 mcg per peptide per dose, administered subcutaneously either once daily (bedtime, aligning with nocturnal growth hormone pulse) or twice daily (morning fasted and bedtime, targeting both major pulse windows). Twice-daily protocols produced slightly higher IGF-1 increases (28–35% vs 20–28% for once-daily) in Phase II data through Q1 2026. Some trials are testing cycling protocols (5 days on / 2 days off) to prevent receptor downregulation during long-term use. The optimal protocol likely depends on individual goals — metabolic improvement vs body composition vs longevity optimization — and may require personalized titration based on IGF-1 response and adverse event tolerance.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA